Shots:
- Merck has reported P-III (KEYNOTE-B96/ENGOT-ov65) trial data assessing Keytruda (400mg, IV, Q6W for ~2yrs.) with CT ± Avastin vs PBO + CT ± Avastin in Pt-resistant recurrent ovarian cancer pts (n=643)
- Trial met its 2EP of improved OS in pts with PD-L1+ tumors, building on previously reported data, which will be presented at ESMO’25; OS data to be reported in future
- Additionally, data from P-II/III (REJOICE-Ovarian01) trial assessing raludotatug deruxtecan in pts with Pt-resistant high-grade ovarian primary peritoneal or fallopian tube cancer will also be presented at the ESMO’25
Ref: Merck | Image: Merck | Press Release
Related News:- Merck Presents P-III (HYPERION) Trial Data of Winrevair (sotatercept-csrk) for Pulmonary Arterial Hypertension at ERS 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
